News
Please contact
Vit Vasista
for more information.
-
REGENX Biosciences Consortium awarded $7.7M Grant for Clinical Development Program using NAV rAAV8 - March 27, 2013
Download the article (pdf)
-
REGENX Biosciences Receives FDA Orphan Designation for Treatment of Familial Hypercholesterolemia - April 10, 2012
Download the article (pdf)
-
REGENX and Asklepios Enter into Agreement for Treatments for Hemophilia A using NAV(TM) rAAV8 - March 08, 2012
Download the article (pdf)
-
REGENX BioSciences Supports Rare Disease Day: Highlights Recent Advances with NAV(TM) Technology - February 29, 2012
-
REGENX Highlights Gene Therapy Advances in the Prevention and Treatment of HIV and Hemophilia B - December 14, 2011
-
REGENX Scientific Founder Discusses The History and Promise of Gene Therapy - October 03, 2011
Click here for the full article.
-
REGENX Biosciences Awarded $2.8 Million NIH Grant for Novel Eye Therapeutic Development Program - May 03, 2011
-
REGENX Biosciences Licenses ARGENT™ Gene Regulation Technology from ARIAD Pharmaceuticals, Inc. - April 20, 2011
-
REGENX BioSciences Supports Rare Disease Day: Highlights Gene Therapy Advances - February 28, 2011
-
REGENX BioSciences Licenses Key Intellectual Property from University of Pennsylvania - March 09, 2009
Download full article (pdf)
